Differentiating Ischemic Stroke from Epileptic Seizure Using Laboratory Biomarkers

A comprehensive review of feasible biomarkers and their temporal characteristics in the emergency department

emergency department medical equipment biomarker testing

Key Insights

Biomarker Panels: Multiple biomarkers such as lactate, prolactin, creatine kinase, and inflammatory markers offer complementary diagnostic value.
Time-Sensitive Changes: Each biomarker has a distinct time frame post-event during which alterations can be observed, critical for accurate interpretation.
Combination Approach: No single marker is definitive; integrating clinical context with a panel of biomarkers optimizes differentiation between stroke and seizure.

Overview

In the setting of an emergency department, rapid differentiation between ischemic stroke and epileptic seizure is crucial. Laboratory biomarkers provide valuable insights that help guide early management in these critical conditions. This synthesis presents a compilation of various markers that have been studied for their ability to aid in distinguishing ischemic strokes from epileptic seizures. Each biomarker discussed below is feasible to obtain in emergency settings, and its diagnostic window—the time period during which a change in the biomarker value remains observable—is a critical component of its utility.

Biomarkers and Their Temporal Dynamics

1. Blood Biomarkers Indicative of Brain Tissue Damage

Glial Structural Proteins: GFAP and S100B

Glial Fibrillary Acidic Protein (GFAP) and S100B are among the glial structural proteins extensively studied in brain injuries. GFAP levels, while primarily utilized in differentiating ischemic stroke from intracerebral hemorrhage, have limited utility in discriminating seizure events directly. S100B, similarly, can be elevated in brain tissue damage incurred during strokes and seizures. These proteins typically increase within several hours after the event, reflecting the extent of brain injury. However, their specificity is restricted, as elevated levels can occur in both conditions.

Matrix Metalloproteinase-9 (MMP-9) and Vascular Markers (vWF, VCAM)

A combination panel including MMP-9, von Willebrand factor (vWF), and Vascular Cell Adhesion Molecule (VCAM) has been shown to distinguish ischemic stroke from healthy controls with high sensitivity (up to 90-92%) and specificity (around 93%). In the acute phase, these biomarkers typically rise within a few hours following the ischemic insult due to inflammatory responses and blood-brain barrier disruption. Their dynamic elevation, however, is not generally observed following epileptic seizures unless there is concomitant brain injury.

2. Biomarkers Specific to Seizure Activity

Serum Prolactin

Serum prolactin is one of the most promising biomarkers for differentiating seizure-related events from other neurological conditions. Prolactin levels rise within 10 to 30 minutes following an epileptic seizure, particularly in generalized tonic-clonic seizures. This elevation can remain detectable for up to 60 minutes post-seizure. Its rapid rise and relatively short diagnostic window allow clinicians to infer a seizure event, although normal prolactin levels may be seen in ischemic stroke unless secondary seizure activity occurs. Its sensitivity is moderate, though its specificity in distinguishing epileptic from psychogenic non-epileptic seizures has been highlighted.

Creatine Kinase (CK)

Creatine kinase is another marker that rises quickly post-seizure, reflecting the intense muscle exertion that occurs, particularly during generalized seizures. Levels can remain elevated for 48-72 hours after the event and provide supporting diagnostic evidence of seizure activity. In contrast, CK usually remains within normal ranges in isolated ischemic stroke cases unless there have been associated muscular injuries.

3. Metabolic and Inflammatory Biomarkers

Lactate

Lactate is a well-known marker that increases due to anaerobic metabolism during intense physical activity such as a seizure. In the context of epileptic events, lactate levels surge and then gradually decrease, typically normalizing within 12 to 24 hours. In ischemic stroke, lactate elevations may be more sustained, reflecting prolonged periods of cellular hypoxia and metabolic compromise. Therefore, while both conditions may exhibit elevated lactate, the pattern and duration are distinguishing factors.

Ammonia

Elevated ammonia levels have been observed in the context of seizures, where postictal blood tests may reveal metabolic disturbances. Ammonia, like lactate, may help infer the metabolic stress induced by a seizure, but its elevation does not persist indefinitely. It is often evaluated in conjunction with other biomarkers to maximize diagnostic accuracy.

C-Reactive Protein (CRP) and Inflammatory Markers

C-reactive protein, a non-specific inflammatory marker, can be elevated in both ischemic stroke and following seizures. However, in stroke, the inflammatory response is generally more pronounced, leading to higher CRP levels that can rise within 6-12 hours of the event and remain elevated for several days. While CRP alone is not sufficiently discriminative, its value increases when used as part of an integrated panel with other more specific biomarkers.

Interleukin-1β (IL-1β)

Interleukin-1β is pivotal in mediating inflammatory responses and has been found to be upregulated in seizure disorders, particularly in cases of generalized tonic-clonic seizures and temporal lobe epilepsy. Not only does IL-1β serve as an indicator of the neuroinflammatory process post-seizure, but it also has prognostic implications in predicting seizure recurrence following an ischemic stroke. The marker’s levels are typically detectable soon after the event and gradually decline as the inflammatory response resolves.

4. Routine Laboratory Tests

Complete Blood Count (CBC) and Delta Neutrophil Index (DNI)

A complete blood count (CBC) is a routine laboratory test in the emergency department that can reveal leukocytosis, frequently observed in the postictal state of seizures. An emerging parameter from the CBC, the Delta Neutrophil Index (DNI), reflects the presence of immature granulocytes in the circulation and serves as a potential marker in identifying epileptic seizures. These values are generally elevated within hours after a seizure and can be integrated into a broader diagnostic framework.

Metabolic Panel (Glucose, Electrolytes, and Renal Function)

The metabolic panel remains an essential tool in the initial evaluation of patients presenting with neurological events. Hypoglycemia, which can incite seizures, contrasts with the stress-induced hyperglycemia occasionally seen in ischemic stroke. In addition to glucose, evaluation of serum sodium, potassium, and other electrolytes provides insight into metabolic and toxic disturbances. These parameters are dynamic and highly sensitive to immediate clinical interventions.

Comparative Summary Table

The following table summarizes the key biomarkers, their utility in differentiating between ischemic stroke and epileptic seizure, and the time frames during which changes in their levels are observable.

Biomarker	Utility/Role	Time Frame Post-Event	Considerations
GFAP & S100B	Indicate brain tissue damage; more prominent in stroke	Hours post-event	Elevated in both conditions but more indicative of stroke
MMP-9, vWF, VCAM	Reflect blood-brain barrier disruption in stroke	Hours after ischemic event	Provides high sensitivity and specificity for stroke
Prolactin	Elevated post-epileptic seizure	10–30 minutes rise; returns to baseline by 60 minutes	Useful for differentiating generalized seizures
Creatine Kinase (CK)	Indicates muscle exertion during seizures	Elevated for 48–72 hours	Normal in isolated stroke without muscular injury
Lactate	Elevated due to anaerobic metabolism during seizures	Peaks shortly post-event; declines over 12–24 hours	Patterns differ in stroke vs. seizure contexts
Ammonia	Reflects metabolic stress post-seizure	Detectable acutely; decreases as metabolic disturbances resolve	Often used in combination with lactate
CRP	Non-specific inflammatory marker	6–12 hours rise; elevated for days	Higher in stroke-induced inflammation
IL-1β	Mediates inflammation and seizure recurrence	Detectable soon after seizure onset; declines with resolution	Useful in predicting post-stroke seizure recurrence
CBC & DNI	Identifies postictal leukocytosis and immature granulocyte elevation	Detectable within hours post-seizure	Can supplement other biomarkers to support seizure diagnosis
Metabolic Panel (Glucose, Electrolytes)	Assesses metabolic derangements	Immediate; fluctuates with clinical intervention	Critical for distinguishing seizure triggers from stroke

Integrated Diagnostic Approach

Given the multifactorial nature of neurological events, a comprehensive evaluation that integrates both clinical examination and laboratory findings is essential. It is important to understand that no single biomarker provides a complete diagnostic picture on its own. Instead, a panel approach utilizing the discussed biomarkers can offer complementary insights. For example, a patient presenting with elevated prolactin and CK levels in tandem with an acute increase in lactate strongly suggests seizure activity, particularly when these changes occur within minutes to hours post-event. In contrast, sustained increases in inflammatory markers (such as CRP) and metabolic disruptions observed via the metabolic panel may lean towards an ischemic stroke diagnosis when correlated with imaging studies and clinical history.

Clinical Considerations

Timing of Biomarker Measurement

The timing of blood sampling is of paramount importance when interpreting the results. For instance, lactate levels in epileptic seizures are best assessed within the first 12–24 hours post-event because they decline as the physiological disturbance normalizes. Prolactin, on the other hand, has a shorter window of diagnostic utility, peaking roughly within 10–30 minutes after seizure onset and returning to baseline within an hour.

Combination with Imaging and Clinical Data

Laboratory biomarkers provide a biochemical snapshot that must be interpreted in the context of imaging modalities such as CT or MRI and clinical findings. Biomarkers like GFAP and S100B may reflect brain injury but require corroboration with imaging data to ascertain the injury’s etiology. A thorough examination, including neurological assessment, is necessary to use these biomarkers most effectively.

Integrating Laboratory Panels

The integration of multiple biomarkers improves the diagnostic power. Emergency department protocols benefit from including routine tests (CBC, metabolic panels) along with more specific assays (prolactin, CK, lactate). This integrated approach is particularly valuable when there is ambiguity in clinical presentation or when multiple concurrent processes (e.g., stroke with secondary seizure) complicate the picture.

Conclusions and Final Thoughts

Differentiating between ischemic stroke and epileptic seizure using laboratory biomarkers in the emergency department is both challenging and essential for guiding prompt and precise treatment. The key biomarkers discussed—ranging from glial structural proteins such as GFAP and S100B, vascular and inflammatory markers like MMP-9, vWF, VCAM, and CRP, to metabolic and seizure-specific indicators including lactate, prolactin, creatine kinase, ammonia, and IL-1β—each contribute unique insights with distinct temporal characteristics.

The value of these biomarkers lies not solely in their individual diagnostic capabilities but in the complementary information they provide when used in concert. Given that these biomarkers change dynamically over time, their interpretation should consider the specific onset-to-testing interval. This time-sensitive assessment is crucial—while lactate levels rapidly decrease post-seizure, prolactin offers a narrow window for confirmation of recent seizure activity, and CK remains elevated over a more extended period.

Clinicians in the emergency department can leverage these findings by establishing a protocol that combines rapid point-of-care testing for markers like lactate and prolactin with routine laboratory evaluations such as the CBC and metabolic panels. In doing so, they can more accurately differentiate between patients suffering from an ischemic stroke and those experiencing an epileptic seizure, thereby optimizing the management strategies for each condition.

In summary, the integration of multiple biomarker assessments, along with correlating clinical and imaging findings, creates a robust framework for differentiation. As research in this domain continues to evolve, these panels may be further refined to improve both the sensitivity and specificity of early diagnostics in critical care settings.